Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)

NCT06090539 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT06090539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06090539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 29, 2023
Completion date
October 28, 2028
Enrollment
460 (estimated)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory non-hodgkin lymphoma